AMIX AUTONOMIX MEDICAL INC

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event

Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET

Access the event

THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the on Thursday, May 22, 2025 at 4:00 PM ET.

As part of the event, of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

The will be available on the page under the section of the Company’s website (). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

(908) 824-0775



EN
14/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the U...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Hu...

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or ...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerv...

 PRESS RELEASE

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bel...

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology,...

 PRESS RELEASE

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansi...

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- –  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch